Patients have greater hope for cures to today’s most complex and challenging diseases thanks to modern specialty medicines, which allow doctors and patients to focus on prevention and avoid hospital care altogether. With the potential to save countless lives and improve so many more, today’s innovative life-enhancing medicines and therapies provide economic value far beyond their cost.
The debate surrounding the value of modern specialty medicines focuses narrowly on one aspect – cost – while ignoring the benefits these medicines bring to patients and our healthcare system. We must focus on the bigger picture. Over the last 50 years, medical innovation has been the source of one-half of all economic growth. The cost of this progress has been relatively modest, and will remain so for the foreseeable future.
As the conversation continues regarding the best path forward to improve healthcare in America, we must avoid a short-sighted approach that all too often refuses to recognize the tremendous value of biopharmaceutical innovation. To do otherwise is a risk that patients cannot afford.
Decades of data shows that the greater access patients have to treatment, the longer and higher quality lives they lead.
It’s time to rethink access to keep pace with innovative treatment advances and recognize the long‐term value of these medicines. We strongly believe that patients must be presented with all treatment options available, regardless of cost, so that, along with their physicians, they can make informed decisions about their best course of medical treatment. It is imperative that patients have meaningful access to these needed medicines.
Now, with innovative specialty medicines, we increasingly have the opportunity to shift the system toward preventing or curing disease. This is the future of medicine. We must recognize the long-term value of specialty medicines to cure disease, prevent suffering and save costs. Patients are counting on us.